(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 14.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Codexis's revenue in 2026 is $70,387,000.On average, 8 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,802,388,597, with the lowest CDXS revenue forecast at $5,138,298,209, and the highest CDXS revenue forecast at $7,891,639,483. On average, 7 Wall Street analysts forecast CDXS's revenue for 2027 to be $7,932,621,560, with the lowest CDXS revenue forecast at $7,213,208,924, and the highest CDXS revenue forecast at $8,772,436,083.
In 2028, CDXS is forecast to generate $9,816,615,772 in revenue, with the lowest revenue forecast at $8,219,496,094 and the highest revenue forecast at $11,404,103,300.